FDA Brief

Warning letters Drugs

FDA warning letter to

Saruhan Kimya Ve Temizlik Urunleri Sanayi Ticaret Anonim Sirketi Corlu Subesi

High riskIssued Nov 6, 2023Posted Nov 14, 2023Center for Drug Evaluation and Research | CDER

FDA found manufacturing violations at Turkish OTC drug maker, including missing identity, release, and stability testing for hand sanitizers.

What happened

FDA reviewed records the firm submitted after three FDA records requests dated June 14, 2022, July 12, 2022, and July 28, 2023. FDA found the firm did not show identity testing of incoming components, did not test ethanol for methanol, did not include identity results in finished-product test reports, skipped microbiological testing because of high alcohol content, and lacked adequate stability data for a two-year shelf life.

What FDA found

  1. The firm did not test each incoming component for identity and did not validate supplier test results; it also did not test ethanol lots for methanol.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  2. Finished OTC drug batches were released without complete identity and strength testing, and the firm skipped microbiological testing based on high alcohol content.

    21 CFR 211.165(a) and 211.165(b)
  3. The firm lacked adequate stability data to support its two-year expiry and did not evaluate stability batches for identity.

    21 CFR 211.166(a)

What FDA wants

Respond in writing within 15 working days with corrective actions and records for component identity testing, finished-product release testing, and stability; if the firm intends to resume U.S. drug manufacturing, FDA recommends a qualified current good manufacturing practice (CGMP) consultant.

Who should pay attention

  • brands and distributors buying OTC hand sanitizers from this contract manufacturer
  • companies relying on supplier test reports for ethanol or other raw materials
  • quality teams handling U.S. import alerts and supplier qualification

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. TCI Co., Ltd BioCosme PABP BRANCH

    FDA warns Taiwan OTC drug contract manufacturer TCI BioCosme over CGMP violations, including incomplete release and ingredient testing.

    High risk
  3. Babikian Healthcare Products CJSC

    FDA warns Babikian Healthcare Products over manufacturing quality failures for over-the-counter drugs, including missing identity and finished-product testing.

    High risk
  4. Stream2Sea, LLC

    FDA found Stream2Sea, an OTC drug maker in Bowling Green, Florida, released drug batches without finished-product testing, raw material identity testing, or validated cleaning.

    Medium